Comparison of Modification of a Bacterial Uricase with N‐hydroxysuccinimide Esters of Succinate and Carbonate of Monomethoxyl Poly(ethylene Glycol)
Chun Zhang,Xiaolan Yang,Ang Gao,Xiaolei Hu,Jun Pu,Hongbo Liu,Juan Feng,Juan Liao,Yuanli Li,Fei Liao
DOI: https://doi.org/10.1002/bab.1215
2014-01-01
Biotechnology and Applied Biochemistry
Abstract:Uricase after modification with monomethoxy poly(ethylene glycol) (mPEG) is currently the sole agent to treat refractory gout. For formulating Bacillus fastidious uricase, succinimidyl carbonate of mPEG-5000 (SC-mPEG5k) and succinimidyl succinate of mPEG-5000 (SS-mPEG5k) were compared. SC-mPEG5k possessed higher purity, comparable reaction rate constant with glycine but lower hydrolysis rate, and stronger effectiveness to modify amino groups. The uricase possessed two types of amino groups bearing a 25-fold difference in reactivity with SC-mPEG5k or SS-mPEG5k at pH 9.2. Oxonate and xanthine concentration-dependently protected the bacterial uricase from inactivation during PEGylation. With SC-mPEG5k at a molar ratio of 200 to uricase subunits and oxonate of 50 mu M, the PEGylated uricase (1) retained about 73% of the original activity, (2) displayed about 10% reactivity to rabbit anti-sera recognizing the native uricase, (3) elicited IgG in rats accounting for about 5% of that by the native uricase, (4) exhibited circulation half-life time of about 25 H in cock plasma in vivo, and (5) concurrently maintained uric acid at lowered levels for over 20 H. Hence, PEGylation with SC-mPEG under the protection of a competitive inhibitor was a practical approach to formulation of the bacterial uricase; protection of enzymes by competitive inhibitors during PEGylation may have universal significance. (c) 2014 International Union of Biochemistry and Molecular Biology, Inc.